Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$14.89 USD
+0.21 (1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.87 -0.02 (-0.13%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CPRX 14.89 +0.21(1.43%)
Will CPRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Other News for CPRX
Catalyst Pharma (CPRX) Receives a Buy from Truist Financial
20 companies screened for quality in a cheap part of the stock market
Edgewise gets EU orphan drug status for muscular dystrophy drug
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024